SYNTHETIC STUDIES ON TUMOR PROMOTERS & INHIBITORS

肿瘤促进剂的综合研究

• 批准号: 7724146
• 负责人: PAUL Anthony WENDER
• 金额: $ 0.36万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-01 至 2009-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7724146
• 关键词: Biological; Biological Assay; Bioluminescence; Cells; Computer Retrieval of Information on Scientific Projects Database; Development; Drug Evaluation; Endopeptidases; Evaluation; Family Study; Funding; Grant; Hybrids; Institution; Lead; Malignant Neoplasms; Paclitaxel; Peptide Hydrolases; Research; Research Personnel; Resistance; Resources; Route; Source; Time; Tissues; Tumor Promoters; United States National Institutes of Health; analog; base; cancer therapy; daphnane; design; extracellular; gnidimacrin; inhibitor/antagonist; laulimalide

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is directed at five specific aims: D.1: The synthesis of gnidimacrin, a potent lead for the treatment of cancer based on PKC targeting; D.2: The development of a general and flexible rout to anticancer leads in the daphnane family and study of their activity; D.3: The synthesis and biological evaluation of daphnane-tigliane hybrids; D.4: The synthesis and biological evaluation of laulimalide analogs, compounds active against taxol resistant cancers; D.5: The design, synthesis, and evaluation of drug and probe transporters involving a real time bioluminescence assay with a specific focus on transporter conjugates that are designed for selective cell or tissue entry based on activation by extracellular proteases

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该项目有五个具体目标：D.1：gnidimacrin的合成，gnidimacrin是一种基于PKC靶向治疗癌症的有效先导化合物; D.2：开发瑞香烷家族抗癌先导化合物的通用和灵活路线并研究其活性; D.3：瑞香烷-惕各烷杂合物的合成和生物学评价; D.4：laulimalide类似物的合成和生物学评价，对紫杉醇耐药性癌症有活性的化合物; D.5：设计，合成，以及涉及真实的时间生物发光测定的药物和探针转运蛋白的评价基于细胞外蛋白酶的激活